Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.
about
Emerging Vaccine TechnologiesAAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing ActivityAutologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeysHuman Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B EnvelopeProgress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).Functional contributions of carbohydrate on AIDS virus glycoproteinImmunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.Protection of macaques with diverse MHC genotypes against a heterologous SIV by vaccination with a deglycosylated live-attenuated SIV.Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopesBiologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys.The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239Influence of glycosylation on the efficacy of an Env-based vaccine against simian immunodeficiency virus SIVmac239 in a macaque AIDS modelBoosting of HIV-1 neutralizing antibody responses by a distally related retroviral envelope protein.Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus.Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strainsIdentification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4.Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages.Envelope-modified single-cycle simian immunodeficiency virus selectively enhances antibody responses and partially protects against repeated, low-dose vaginal challengeAlgal lectins as potential HIV microbicide candidatesDiversity of envelope genes from an uncloned stock of SIVmac251.The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.Immunogen sequence: the fourth tier of AIDS vaccine design.Influence of N-linked glycosylation of porcine reproductive and respiratory syndrome virus GP5 on virus infectivity, antigenicity, and ability to induce neutralizing antibodiesNon-human primate models for AIDS vaccine research.Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies.The genetic bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant virus from the maternal viral population.Systematic analysis of intracellular trafficking motifs located within the cytoplasmic domain of simian immunodeficiency virus glycoprotein gp41Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane proteinThe roles of nonhuman primates in the preclinical evaluation of candidate AIDS vaccines.Requirement of diverse T-helper responses elicited by HIV vaccines: induction of highly targeted humoral and CTL responses.Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.Induction of antibody-mediated neutralization in SIVmac239 by a naturally acquired V3 mutation.Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.Recombinant AAV Vectors for Enhanced Expression of Authentic IgG.Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeysPathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies.Analysis of SIVmac Envelope-Specific Antibodies Selected Through Phage Display.
P2860
Q26783764-D85406A7-E665-4F38-90CD-E5F84D6D60FEQ27318266-4EEB28B4-572C-4802-893C-8DF42D8B14E3Q28751926-55AA0C8C-C327-4A2D-A66D-A036208A58DFQ29307502-4EFCB976-1091-424F-9948-ABB1F9D7DC3AQ30379200-FB36182C-BD0A-4FF9-8D34-09814B1D97B5Q30397572-80750E61-D662-476B-B8BA-80C15EC609E3Q33402455-1C80D7AB-07CF-4B92-BD1D-2262663B5BDBQ33638458-B34352EE-E55C-43F4-89E2-F641ADD95202Q33648910-BFD0DB89-829C-48F8-ABC2-5E5F14D7D93FQ33780524-3E4F5759-E506-4366-95F9-E39A8AD815E2Q33780980-A19A804C-499D-4E48-9A41-0563CA9D6389Q33788792-585E244B-04E4-4C25-B825-8BA76480C81CQ33843131-E2525F36-1C77-438A-9D4D-96755059C42BQ33912052-C6E32CEF-A793-4C00-A42F-16F717C369C4Q33955745-EB7943D2-B8D7-4063-8586-94854E753A79Q33984296-13D173ED-0A53-40A1-ACE9-A55C0408E434Q33984358-033A62C9-B821-41F9-9DCE-02DDEE273641Q33984371-1E4C7AC7-2705-4BD5-85A9-83547EA6233BQ34120130-B371C5B6-942C-4FDB-9D39-05A3D93B461BQ34178259-0EFC2922-AC64-4E6F-8540-A79342347318Q34291727-15B31774-BF70-4F7F-9E7B-F8B1709C48B4Q34315382-F5BD58DE-A85B-458C-ABA1-2EBFD953550BQ34317025-8898F787-B601-43EA-9759-52BCD1FB697BQ34337482-E257702B-32BC-4E85-84BF-7A40F47EF13EQ34545996-CF024D13-E765-49BD-A687-D14A84C5B234Q34715769-8B30892E-7731-401F-B270-88AF22AF816DQ35102328-4E36F518-3B68-4424-B619-698DC2606BA6Q35140408-D6E0154C-FCDB-4CB6-9B2B-70AC3F4A763FQ35494155-3D283A62-772B-4D1E-9D5D-03456B5C6A80Q35665722-E0EA3ACA-455C-4D4A-B453-C32727868AB7Q35851774-DEEF46F7-8874-465A-82B9-38A9E3ED17D1Q35851778-12CF1F1A-ECE1-4595-8512-7018CA527A4EQ35914280-CEE4D8EB-C643-407D-B87D-5D6D685092D5Q35914362-D68542DD-2CE0-4798-8DF9-1A10BB93F5CEQ35955770-F4B6F028-0276-47FB-8168-B4A84F729A0FQ35985519-396F950C-9B15-4519-B57C-BDF38DCED522Q36058890-AF4DA18D-E3B2-45A2-9EF8-C5E7FB897DF1Q36155555-F5043434-BBC8-4387-A6AA-E17A115D9BD5Q36171962-0B992134-B389-42BA-A731-5FDA5DDC85D2Q36246070-B94E1DF9-BEAC-42C9-BD4C-27CA8308450C
P2860
Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Assorted mutations in the enve ...... oad spectrum of specificities.
@en
Assorted mutations in the enve ...... oad spectrum of specificities.
@nl
type
label
Assorted mutations in the enve ...... oad spectrum of specificities.
@en
Assorted mutations in the enve ...... oad spectrum of specificities.
@nl
prefLabel
Assorted mutations in the enve ...... oad spectrum of specificities.
@en
Assorted mutations in the enve ...... oad spectrum of specificities.
@nl
P2093
P2860
P1433
P1476
Assorted mutations in the enve ...... oad spectrum of specificities.
@en
P2093
Dennis R Burton
Hannah Sanford
James E Robinson
Linda Schwall
Ronald C Desrosiers
Welkin E Johnson
P2860
P304
9993-10003
P356
10.1128/JVI.77.18.9993-10003.2003
P407
P577
2003-09-01T00:00:00Z